Skip to main content

Table 2 Clinical trial registrations on allogeneic CAR-T cell infusion after allo-HSCT in B cell malignancies

From: Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Center Disease Status of disease Activation motif of CAR Drugs Numbers of CAR-T cells Phase Status Registered ID
National Cancer Institute (NCI), American B cell cancer Either did not respond to or recurred after allogeneic transplantation Not shown Cy 180 mg/m2 for 3 days and pentostatin 4 mg/m2 for 1 day Dose escalation I Suspended NCT01087294
University of Pennsylvania, American CD19+ ALL Relapse after allogeneic transplantation 4-1BB Not shown Not shown (split infusion over 3 days) I Completed NCT01551043
Department of Hematology, Xinqiao Hospital, China B-ALL Molecular relapse after allogeneic transplantation Not shown No 1 × 106/kg II Recruiting ChiCTR-OOC-16008447
  1. Note: The trials are registered at ClinicalTrials.gov and http://www.chictr.org.cn/index.aspx. Search was performed on December 18, 2016.
  2. CAR-T chimeric antigen receptors redirected T cells, allo-HSCT allogeneic stem cell transplantation, Cy cyclophosphamide, B-ALL B cell acute lymphoblastic leukemia